deltatrials
Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT05057013

A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

A Cancer Research UK Phase I/IIa Open Label, Dose Escalation and Expansion Trial of HMBD-001 (an Anti-HER3 Monoclonal Antibody) Given Intravenously as a Single Agent and in Combination in Patients With Advanced HER3 Positive Solid Tumours

Sponsor: Cancer Research UK

Conditions Bladder Cancer Castration-resistant Prostate Cancer Cervical Cancer Endometrial Cancer Gastric Cancer Hepatocellular Carcinoma (HCC) Melanoma Non-small Cell Lung Cancer (NSCLC) Oesophageal Cancer Ovarian Cancer Pancreatic Cancer RAS Wild Type Colorectal Cancer Squamous Cell Cancer of the Head and Neck Triple Negative Breast Cancer
Interventions HMBD-001 HMBD-001 and enzalutamide
Updated 9 times since 2021 Last updated: Aug 6, 2025 Started: Nov 10, 2021 Primary completion: Nov 30, 2025 Completion: Nov 30, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Bladder Cancer and Castration-resistant Prostate Cancer and is currently ongoing. Cancer Research UK leads this study, which shows 9 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshotNot Yet Recruiting~Nov 2021 – ~Jan 2022 · 2 months · monthly snapshotRecruiting~Jan 2022 – ~Apr 2023 · 15 months · monthly snapshotRecruiting~Apr 2023 – ~Jul 2024 · 15 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotRecruiting~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshotRecruiting~Nov 2024 – ~Jan 2025 · 2 months · monthly snapshotRecruiting~Jan 2025 – ~Sep 2025 · 8 months · monthly snapshotRecruiting~Sep 2025 – present · 8 months · monthly snapshotActive Not Recruiting

Change History

9 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Jan 2025 — Sep 2025 [monthly]

    Recruiting PHASE1/PHASE2

  3. Nov 2024 — Jan 2025 [monthly]

    Recruiting PHASE1/PHASE2

  4. Sep 2024 — Nov 2024 [monthly]

    Recruiting PHASE1/PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 4 earlier versions

  1. Apr 2023 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

  2. Jan 2022 — Apr 2023 [monthly]

    Recruiting PHASE1_PHASE2

  3. Nov 2021 — Jan 2022 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  4. Oct 2021 — Nov 2021 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Cancer Research UK
  • Hummingbird Bioscience
Data source: Cancer Research UK

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations